What is Nuedexta (dextromethorphan hydrobromide and quinidine sulfate) used for?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 11, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Research

Nuedexta Uses

  • Nuedexta, a combination of dextromethorphan hydrobromide and quinidine sulfate, is primarily used to treat pseudobulbar affect (PBA) 1, 2, 3, 4, 5.
  • PBA is a disorder of emotional regulation, characterized by uncontrollable outbursts of laughing and/or crying that are disproportionate to the emotions being experienced 2, 4, 5.
  • Nuedexta has been shown to be effective in reducing the severity of PBA in patients with amyotrophic lateral sclerosis (ALS) and multiple sclerosis 2, 5.
  • The drug has also been used off-label to improve bulbar function in people with ALS, with or without PBA 1.
  • Nuedexta's mechanisms of action, including its effects on sigma-1 receptors and glutamate excitotoxicity, may contribute to its potential benefits in treating PBA and other neurological disorders 1, 2.

Treatment of PBA

  • Nuedexta is indicated in the US for the treatment of PBA, and has been shown to be effective in reducing the rate of PBA episodes per day 5.
  • The drug has been associated with a significantly greater decrease in the rate of PBA episodes per day compared to placebo in clinical trials 5.
  • Nuedexta has been generally well tolerated, although it can cause dosage-dependent corrected QT interval (QTc) prolongation 5.
  • The drug may be a viable treatment alternative for PBA, particularly in patients who have not responded to other treatments such as antidepressants 3, 4.

References

Research

ALSUntangled #71: Nuedexta.

Amyotrophic lateral sclerosis & frontotemporal degeneration, 2024

Research

Dextromethorphan/quinidine sulfate for pseudobulbar affect.

Drugs of today (Barcelona, Spain : 1998), 2008

Research

Dextromethorphan/quinidine for the treatment of pseudobulbar affect.

The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists, 2014

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.